Analona Therapeutics develops antibody-based therapies targeting key facilitators of metabolite transport to improve treatment outcomes for pancreatic cancer. By focusing on novel therapeutic targets identified through extensive research, the company aims to provide patients and healthcare providers with effective, targeted treatment options.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pancreatic cancer treatment outcomes remain poor due to the limited effectiveness of existing therapies. Current treatments often fail to address the metabolic dependencies of pancreatic cancer cells, hindering their ability to be eradicated effectively. New therapeutic targets and approaches are needed to improve patient outcomes.
Solution
Analona Therapeutics is developing antibody-based therapies that target key facilitators of metabolite transport in pancreatic cancer cells. By blocking these transporters, the therapies aim to disrupt the metabolic pathways that fuel cancer growth and survival. This targeted approach seeks to improve treatment efficacy and patient outcomes by specifically addressing the unique metabolic vulnerabilities of pancreatic cancer. The company's research has identified novel targets and mechanisms of action, leading to the development of innovative therapeutic candidates.
Target Audience
The primary target audience includes pancreatic cancer patients and healthcare providers specializing in oncology.
Features
- Antibody-based therapeutics designed to target specific metabolite transporters.
- Focus on disrupting metabolic pathways critical for pancreatic cancer cell survival.
- Novel therapeutic targets identified through extensive pancreatic cancer research.
- Aims to improve treatment outcomes for pancreatic cancer patients.